We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+30.14%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$415M
AUM Growth
-$1.65M
Cap. Flow
-$44.5M
Cap. Flow %
-10.72%
Top 10 Hldgs %
57.35%
Holding
50
New
15
Increased
7
Reduced
16
Closed
10

Top Buys

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$24M
2
HRTX icon
Heron Therapeutics
HRTX
+$22.1M
3
PLRX icon
Pliant Therapeutics
PLRX
+$13.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.5M
5
BBIO icon
BridgeBio Pharma
BBIO
+$10.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$24M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$18.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$14.5M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$11.7M
5
NKTR icon
Nektar Therapeutics
NKTR
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
26
DELISTED
Generation Bio
GBIO
$4.38M 1.05%
+82,508
New +$5.16M
NGM
27
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.14M 1%
+316,256
New +$4.79M
MLTX icon
28
MoonLake Immunotherapeutics
MLTX
$1.57B
$3.82M 0.92%
492,000
+60,000
+14% +$424K
IMCR icon
29
Immunocore
IMCR
$1.72B
$3.69M 0.89%
+78,527
New +$3.74M
LRMR icon
30
Larimar Therapeutics
LRMR
$397M
$3.63M 0.87%
+1,135,000
New +$2.84M
DTIL icon
31
Precision BioSciences
DTIL
$180M
$3.52M 0.85%
90,360
-101,487
-53% -$4.82M
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
$2.8M 0.67%
+799,439
New +$2.87M
PVLA
33
Palvella Therapeutics
PVLA
$1.99B
$2.26M 0.54%
24,568
-6,838
-22% -$882K
ICPT
34
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.47M 0.35%
+105,000
New +$1.69M
GRCL
35
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$1.45M 0.35%
+449,049
New +$1.46M
DNTH icon
36
Dianthus Therapeutics
DNTH
$5.84B
$1.44M 0.35%
63,693
-9,432
-13% -$258K
NKTR icon
37
Nektar Therapeutics
NKTR
$2.39B
$1.43M 0.35%
29,855
-180,145
-86% -$10.7M
DAWN
38
DELISTED
Day One Biopharmaceuticals
DAWN
$1.42M 0.34%
+70,621
New +$1.5M
SYRE icon
39
Spyre Therapeutics
SYRE
$8.54B
$1.31M 0.32%
100,000
– –
SLN
40
Silence Therapeutics
SLN
$495M
$692K 0.17%
68,915
-332,534
-83% -$3.5M
ALNY icon
41
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-150,000
Closed -$21.9M
ANAB icon
42
AnaptysBio
ANAB
$1.58B
– –
-453,118
Closed -$9.2M
CYTK icon
43
Cytokinetics
CYTK
$10.5B
– –
-610,000
Closed -$24M
KNSA icon
44
Kiniksa Pharmaceuticals
KNSA
$5.8B
– –
-1,204,028
Closed -$11.7M
NBIX icon
45
Neurocrine Biosciences
NBIX
$16.8B
– –
-75,000
Closed -$7.31M
RNAM
46
DELISTED
Avidity Biosciences
RNAM
– –
-500,000
Closed -$7.26M
SRPT icon
47
Sarepta Therapeutics
SRPT
$1.57B
– –
-193,900
Closed -$14.5M
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-149,000
Closed -$18.9M
KRTX
49
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-54,900
Closed -$6.95M
KDNY
50
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-336,731
Closed -$5.89M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Great Point Partners held 50 positions worth $415M, down 0.4% from $417M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners withdrew a net $44.5M in Q3 2022, closing 10 positions and reducing 16 holdings. Its most notable exit was Cytokinetics, an estimated $24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Heron Therapeutics worth $23.5M.

  • Great Point Partners's largest Q3 2022 buy was Heron Therapeutics: 5,645,161 shares worth $23.5M.
  • Great Point Partners added most to Alpine Immune Sciences Inc in Q3 2022, an estimated $24M increase.
  • Great Point Partners's biggest Q3 2022 reduction was Nektar Therapeutics, cutting an estimated $10.7M.
  • Great Point Partners fully exited Cytokinetics in Q3 2022, selling an estimated $24M.
  • Great Point Partners's ten largest holdings make up 57% of its $415M portfolio in Q3 2022.
  • Great Point Partners opened 15 new positions and closed 10 in Q3 2022.
  • Great Point Partners's portfolio value fell 0.4% quarter-over-quarter to $415M.

Based on Great Point Partners's 13F filing for Q3 2022, filed 14 Nov 2022.